Table of Contents Revenue Cost of Goods Sold Research and Development Expense The decrease in research and development expense was primarily due to: ● a decrease of $1.0 million related to the development of additional presentations of UDENYCA. Three Months Ended March 31, (in thousands) 2023 2022 Change Selling, general and administrative $49,153 $48,753 $ 400 | --- | --- | --- | --- | --- | --- | --- | --- | |--------------------|-------|-------|-----------|--------|-------|-------|--------| | | | | | | | ...

• Pursue other registration opportunities • TIGIT, ILT4, other combinations Combination therapy provides best opportunity to extend patient survival • Establish toripalimab as SOC in NPC upon approval anticipated in 2023 Platform for Combination Development CIMERLI™ Tracking to the UDENYCA® Success Story Agenda Featured at plenary session External Scientific Validation Progression-Free Survival by BIRC per RECIST v1.1 17 Toripalimab has demonstrated compelling NPC treatment effect; BLA PDUFA Dec 23, 2022 mi ...

Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2022 Earnings Conference Call March 6, 2023 5:00 PM ET Company Participants Marek Ciszewski - SVP, IR Denny Lanfear - CEO Theresa Lavallee - Chief Development Officer Rosh Dias - Chief Medical Officer Paul Reider - Chief Commercial Officer McDavid Stilwell - CFO Conference Call Participants Salim Syed - Mizuho Douglas Tsao - HC Wainwright Chris Schott - JPMorgan Jason Gerberry - Bank of America Ash Verma - UBS Operator Thank you for standing by, and welcome to Cohe ...

If any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. In addition, our CROs are not our employees, and except for remedies available to us under our agreements with such CROs, we cannot control whether or not they devote sufficient time and resources to our on-going nonclinical and clinical programs. If CROs do not successfully carry out their contractual duties or obligations or meet ...

Coherus BioSciences, Inc. (NASDAQ:CHRS) Q3 2022 Earnings Conference Call November 8, 2022 5:00 PM ET Company Participants Marek Ciszewski - Senior Vice President, Investor Relations Denny Lanfear - Chief Executive Officer Theresa Lavallee - Chief Development Officer Rosh Dias - Chief Medical Officer Paul Reider - Chief Commercial Officer McDavid Stilwell - Chief Financial Officer Conference Call Participants Salim Syed - Mizuho Douglas Tsao - HC Wainwright Georgi Yordanov - Cowen Steve Boland - Bank of Amer ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36721 Coherus BioSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 27-3615821 (State or ot ...

Coherus BioSciences, Inc. (NASDAQ:CHRS) Q2 2022 Earnings Conference Call August 4, 2022 5:00 PM ET Company Participants Marek Ciszewski – Investor Relations Denny Lanfear – Chief Executive Officer Rosh Dias – Chief Medical Officer Paul Reider – Chief Commercial Officer McDavid Stilwell – Chief Financial Officer Conference Call Participants Ken Cacciatore – Cowen and Company Douglas Tsao – H.C. Wainwright & Company Jason Gerberry – Bank of America Ash Verma – UBS Operator Ladies and gentlemen, thank you for ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36721 Coherus BioSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 27-3615821 (State or other j ...

Coherus BioSciences, Inc. (NASDAQ:CHRS) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants McDavid Stilwell - CFO Denny Lanfear - President, CEO, and Chairman Paul Reider - CCO Theresa LaVallee - CDO Conference Call Participants Balaji Prasad - Barclays Jason Gerberry - Bank of America Georgi Yordanov - Cowen and Company Operator Good day, and thank you for standing by. Welcome to the Coherus Biosciences Inc. First Quarter 2022 Earnings Conference Call. At this time, all participan ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36721 Coherus BioSciences, Inc. (Exact name ...